Delivery Order SPE2DR25D1106-SPE2DR26FJH2A
- Not listed
- The Defense Logistics Agency awarded a $1,282.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension in 60 mL quantities, with completion targeted for December 10, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $2,648.22 firm fixed price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), with an ultimate completion date of November 5, 2025. This non-set-aside contract represents a single pharmaceutical delivery under the company's broader federal supply arrangements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,334.63 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of May 28, 2025. This is a firm fixed price, non-set-aside delivery order issued under a competitive award process. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military...
- The Defense Logistics Agency awarded a $1,030.10 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with an ultimate completion date of December 11, 2025. This is a firm fixed-price, non-set-aside contract utilizing a competitive award process. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal healthcare vendor that supplies a comprehensive portfolio of medications and medical...
- The Defense Logistics Agency awarded a $2,442.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), with an ultimate completion date of October 24, 2025. This non-set-aside contract represents a competitively awarded delivery order under AmerisourceBergen's existing pharmaceutical supply vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) valued at $1,740.04 under a firm fixed-price contract type. This delivery order, which has an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a competitive delivery order valued at $1,971.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. The award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, valued at $1,082.52 under a firm fixed-price contract. This delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a $2,566.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), with an ultimate completion date of August 4, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity, valued at $2,638.27. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and is classified as a delivery order, with an ultimate completion date of November 4, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves...
- SPE2DR25D1106Indefinite Delivery Contract
- SPE2DR25D1106-SPE2DR26FJH2ADelivery Order
The Defense Logistics Agency awarded a $2,311.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (60 mL) on January 12, 2026, with completion targeted for January 13, 2026. This delivery order is a non-set-aside contract executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2031. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor serving military and veteran healthcare systems. The company has demonstrated consistent capability to fulfill federal procurement requirements through open competition, with its contract portfolio encompassing medications across diverse therapeutic areas including neurological treatments, pain management, diabetes medications, and antibiotics. The company's ability to meet federal standards is evidenced by its extensive history of competitively awarded delivery orders with DLA and its role as a key supplier supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 1/11/26 |